Novel drug composition for curing hepatitis c virus
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- WATERSTONE PHARMA WUHAN
- Publication Date
- 2013-06-05
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 1
Abstract
Description
Technical field:
[0001] The present invention relates to a novel antiviral pharmaceutical composition, which comprises 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]- (4S)-(4-hydroxyphenyl)-2-propanolactam (ezetimibe, Ezetimibe, structural formula see figure 1 ) or its pharmaceutically acceptable derivatives, and anti-HCV (hepatitis C virus) drugs are selected from Boceprevir (BOC), Telaprevir (TVR), long-acting interferon (PEG-IFNα ), interferon (IFNα), ribavirin (Ribavirin) one or more of the pharmaceutical composition and the method for treating HCV infection, belong to the field of pharmaceutical preparations. Background technique:
[0002] Hepatitis C virus, referred to as hepatitis C, hepatitis C, is a kind of viral hepatitis caused by hepatitis C virus (Hepatitis C virus, HCV) infection, mainly through blood transfusion, acupuncture, drug abuse, etc., according to the World Health Organization Organization statistics show that the global HCV infecti...